BIOMARIN PHARMACEUTICAL INC
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Three and Six Months Ended June 30, 2026 and 2025
(In thousands, except per share amounts)
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| REVENUES: | ||||
| Net product revenues | $984,393 | $812,982 | $1,744,471 | $1,547,626 |
| Royalty and other revenues | 5,315 | 12,428 | 11,445 | 22,929 |
| Total revenues | 989,708 | 825,410 | 1,755,916 | 1,570,555 |
| OPERATING EXPENSES: | ||||
| Cost of sales | 202,795 | 150,090 | 397,794 | 301,648 |
| Research and development | 206,952 | 161,308 | 385,748 | 320,039 |
| Selling, general and administrative | 395,549 | 232,279 | 653,839 | 438,395 |
| Intangible asset amortization | 73,492 | 4,846 | 77,975 | 9,693 |
| Total operating expenses | 878,788 | 548,523 | 1,515,356 | 1,069,775 |
| INCOME FROM OPERATIONS | 110,920 | 276,887 | 240,560 | 500,780 |
| Interest income | 10,480 | 18,827 | 33,040 | 37,840 |
| Interest expense | (63,295) | (2,679) | (78,253) | (5,542) |
| Other income, net | 3,279 | 4,833 | 7,240 | 2,879 |
| INCOME BEFORE INCOME TAXES | 61,384 | 297,868 | 202,587 | 535,957 |
| Provision for income taxes | 16,622 | 57,336 | 52,298 | 109,739 |
| NET INCOME | $44,762 | $240,532 | $150,289 | $426,218 |
| EARNINGS PER SHARE, BASIC | $0.23 | $1.25 | $0.78 | $2.23 |
| EARNINGS PER SHARE, DILUTED | $0.23 | $1.23 | $0.77 | $2.19 |
| Weighted average common shares outstanding, basic | 193,423 | 191,907 | 192,959 | 191,440 |
| Weighted average common shares outstanding, diluted | 194,467 | 197,091 | 194,147 | 196,643 |
| COMPREHENSIVE INCOME | $40,216 | $176,816 | $154,979 | $320,000 |
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, 2026 and December 31, 2025
(In thousands, except share amounts)
| June 30, 2026 | December 31, 2025 ⁽¹⁾ | |
|---|---|---|
| ASSETS · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $874,005 | $1,311,679 |
| Short-term investments | — | 248,930 |
| Accounts receivable, net | 1,061,047 | 908,214 |
| Inventory | 1,782,524 | 1,298,883 |
| Other current assets | 254,047 | 185,784 |
| Total current assets | 3,971,623 | 3,953,490 |
| Noncurrent assets: | ||
| Long-term investments | — | 492,242 |
| Property, plant and equipment, net | 989,994 | 952,508 |
| Intangible assets, net | 4,879,367 | 213,837 |
| Goodwill | 655,745 | 196,199 |
| Deferred tax assets | 888,575 | 1,508,697 |
| Other assets | 338,138 | 277,049 |
| Total assets | $11,723,442 | $7,594,022 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $1,005,793 | $759,031 |
| Current portion of long-term debt, net | 658,203 | — |
| Total current liabilities | 1,663,996 | 759,031 |
| Noncurrent liabilities: | ||
| Long-term debt, net | 3,527,939 | 597,176 |
| Other long-term liabilities | 209,815 | 150,816 |
| Total liabilities | 5,401,750 | 1,507,023 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectively | 194 | 192 |
| Additional paid-in capital | 6,037,019 | 5,956,582 |
| Company common stock held by the Nonqualified Deferred Compensation Plan | (11,233) | (10,508) |
| Accumulated other comprehensive loss | (8,783) | (13,473) |
| Retained earnings | 304,495 | 154,206 |
| Total stockholders’ equity | 6,321,692 | 6,086,999 |
| Total liabilities and stockholders’ equity | $11,723,442 | $7,594,022 |
(1)December 31, 2025 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Three and Six Months Ended June 30, 2026 and 2025
(In thousands)
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Shares of common stock, beginning balances (1) | 193,269 | 191,756 | 192,300 | 190,761 |
| Issuances under equity incentive plans | 266 | 246 | 1,235 | 1,241 |
| Shares of common stock, ending balances | 193,535 | 192,002 | 193,535 | 192,002 |
| Total stockholders' equity, beginning balances (1) | $6,212,107 | $5,793,459 | $6,086,999 | $5,657,990 |
| Common stock: | ||||
| Beginning balances (1) | 193 | 192 | 192 | 191 |
| Issuances under equity incentive plans, net of tax | 1 | — | 2 | 1 |
| Ending balances | 194 | 192 | 194 | 192 |
| Additional paid-in capital: | ||||
| Beginning balances (1) | 5,966,868 | 5,794,302 | 5,956,582 | 5,802,068 |
| Issuances under equity incentive plans, net of tax | 4,728 | 5,894 | (32,940) | (43,439) |
| Stock-based compensation | 64,639 | 50,944 | 112,651 | 92,561 |
| Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC) | 784 | 497 | 726 | 447 |
| Ending balances | 6,037,019 | 5,851,637 | 6,037,019 | 5,851,637 |
| Company common stock held by the NQDC: | ||||
| Beginning balances (1) | (10,450) | (11,177) | (10,508) | (11,227) |
| Common stock held by the NQDC | (783) | (497) | (725) | (447) |
| Ending balances | (11,233) | (11,674) | (11,233) | (11,674) |
| Accumulated other comprehensive loss: | ||||
| Beginning balances (1) | (4,237) | 19,151 | (13,473) | 61,653 |
| Other comprehensive income (loss) | (4,546) | (63,716) | 4,690 | (106,218) |
| Ending balances | (8,783) | (44,565) | (8,783) | (44,565) |
| Retained earnings (accumulated deficit) | ||||
| Beginning balances (1) | 259,733 | (9,009) | 154,206 | (194,695) |
| Net income | 44,762 | 240,532 | 150,289 | 426,218 |
| Ending balances | 304,495 | 231,523 | 304,495 | 231,523 |
| Total stockholders' equity, ending balances | $6,321,692 | $6,027,113 | $6,321,692 | $6,027,113 |
(1)The beginning balances for the six-month periods were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 26, 2026.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Six Months Ended June 30, 2026 and 2025
(In thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income | $150,289 | $426,218 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 114,049 | 40,632 |
| Non-cash interest expense | 27,912 | 1,320 |
| Stock-based compensation | 119,152 | 85,231 |
| Impairment of assets | — | 2,967 |
| Deferred income taxes | 2,261 | 61,771 |
| Unrealized foreign exchange gains | (4,046) | (5,306) |
| Other | (5,534) | (4,633) |
| Changes in operating assets and liabilities, net of effects of business acquired: | ||
| Accounts receivable, net | (46,005) | (156,124) |
| Inventory | 12,334 | (72,462) |
| Other current assets | (23,589) | (15,092) |
| Other assets | 9,005 | (13,505) |
| Accounts payable and accrued liabilities | 26,265 | 3,111 |
| Other long-term liabilities | 6,667 | 5,537 |
| Net cash provided by operating activities | 388,760 | 359,665 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property, plant and equipment | (49,739) | (33,869) |
| Maturities and sales of investments | 767,277 | 195,738 |
| Purchases of investments | (25,792) | (202,433) |
| Purchase of intangible assets | (5,433) | (266) |
| Acquisition of Amicus, net of cash acquired | (5,067,630) | — |
| Other | 4,966 | — |
| Net cash used in investing activities | (4,376,351) | (40,830) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from exercises of awards under equity incentive plans | 6,655 | 7,707 |
| Taxes paid related to net share settlement of equity awards | (39,504) | (51,089) |
| Payments of contingent consideration | — | — |
| Proceeds from borrowings | 3,650,000 | — |
| Payments of debt issuance costs | (65,604) | — |
| Net cash provided by (used in) financing activities | 3,551,547 | (43,382) |
| Effect of exchange rate changes on cash | (1,630) | (4,479) |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (437,674) | 270,974 |
| Cash and cash equivalents: | ||
| Beginning of period | $1,311,679 | $942,842 |
| End of period | $874,005 | $1,213,816 |
| SUPPLEMENTAL CASH FLOW DISCLOSURES: | ||
| Cash paid for interest | $3,716 | $3,637 |
| Cash paid for income taxes | $53,504 | $62,385 |
| SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||
| Accounts payable and accrued liabilities related to fixed assets | $8,025 | $9,694 |
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(1)BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations
BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
Basis of Presentation
These Condensed Consolidated Financial Statements have been prepared pursuant to U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although management believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2026 or any other period.
On April 27, 2026, the Company completed the acquisition of Amicus Therapeutics, Inc. (Amicus). The results of Amicus’ operations, along with the preliminary estimated fair values of assets acquired and liabilities assumed in the acquisition, have been included in the Condensed Consolidated Financial Statements since the closing of the acquisition on April 27, 2026. Refer to Note 2 –Acquisitions for additional details related to the Amicus acquisition.
Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.
Use of Estimates
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.
Significant Accounting Policies
There were no changes to the Company’s significant accounting policies during the six months ended June 30, 2026, other than the update to the foreign currency policy following the acquisition of Amicus, as described below. The Company’s significant accounting policies are disclosed in Note 1 –Business Overview and Significant Accounting Policies to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Foreign Currency
While the functional currency of the Company and certain subsidiaries continues to be the U.S. Dollar (USD), the functional currency of certain acquired foreign subsidiaries is their respective local currency.
For subsidiaries whose functional currency is the USD, monetary assets and liabilities denominated in foreign currencies are remeasured using period-end exchange rates and non-monetary assets and liabilities are remeasured using historical exchange rates. Foreign currency transaction gains and losses resulting from the remeasurement are recognized in Other Income (Expense), Net in the Consolidated Statements of Income.
For subsidiaries whose functional currency is their local currency, assets and liabilities are translated into USD using exchange rates in effect at the balance sheet date and income and expense items are translated using average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of these certain foreign subsidiaries into USD are recorded in Accumulated Other Comprehensive Income (Loss), a separate component of stockholders' equity. Foreign currency transaction gains and losses arising from transactions denominated in a currency other than the subsidiary’s functional currency are recognized in Other Income (Expense), Net in the Consolidated Statements of Income.
Recent Accounting Pronouncements
There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during the six months ended June 30, 2026, as compared to the recent accounting pronouncements described in Note 1 to the Company’s Consolidated Financial Statements of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, that the Company believes are of significance or potential significance to the Company.
(2)ACQUISITIONS
On April 27, 2026, the Company completed the acquisition of Amicus, a publicly traded, global, biotechnology company. Under the terms of the merger agreement, the Company acquired all outstanding shares of Amicus common stock, and upon closing, Amicus became a wholly-owned subsidiary of BioMarin. The acquisition is expected to strengthen the Company's commercial portfolio by addingtwo new treatments to its existing portfolio of medicines that target lysosomal storage diseases: GALAFOLD (migalastat), the first oral treatment for Fabry disease, and POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat), a two-component therapy for Pompe disease. In connection with the acquisition, the Company also received U.S. rights to BMN 820 (formerly DMX-200), a potential first-in-class oral CCR2 inhibitor for focal segmental glomerulosclerosis (FSGS), a rare fatal kidney disease in Phase 3 development.
The total purchase consideration for the acquisition of Amicus was $5.3 billion, which consisted of cash consideration paid to former Amicus shareholders, cash payments related to the settlement of equity awards and stock options, the settlement of Amicus’ outstanding debt, and certain seller transaction costs paid by the Company on behalf of Amicus.
The transaction was financed through a combination of cash on hand and non-convertible debt financing. In connection with the acquisition, the Company issued $850.0 million in aggregate principal amount of 5.5% senior unsecured notes in February 2026, and obtained senior secured term loan facilities for $2.8 billion in aggregate principal in April 2026. Refer to Note 7 –Debt for additional details.
The transaction has been accounted for as a business combination using the acquisition method of accounting, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. The Company recorded acquisition-related costs of $30.4 million and $32.8 million in Selling, General and Administrative (SG&A) on the Company’s Condensed Consolidated Statements of Comprehensive Income during the three and six months ended June 30, 2026, respectively.
Total consideration transferred for the acquisition of Amicus is summarized as follows:
| Cash paid to Amicus' shareholders | $4,563,463 |
|---|---|
| Cash settlement towards Amicus’ RSUs and PSUs | 142,636 |
| Cash settlement towards pre-combination portion of stock options (1) | 62,946 |
| Transaction expenses settled by the Company on behalf of Amicus | 121,596 |
| Amicus debt repayment by the Company on behalf of Amicus (2) | 432,920 |
| Total consideration | $5,323,561 |
(1)Cash settlement towards the stock options consists of $51.9 million paid for vested stock options and $11.0 million paid for the pre-combination portion of unvested stock options that were accelerated as part of the acquisition. The fair value of the unvested stock options attributable to the post-combination period of $13.0 million is included in SG&A on the Company’s condensed consolidated statements of comprehensive income during the three and six months ended June 30, 2026
(2)Includes cash settlement related to repayment of outstanding debt, prepayment penalty and accrued interest.
The following table summarizes the preliminary purchase price allocation of the assets acquired and liabilities assumed as of April 27, 2026:
| Cash and cash equivalents | $255,931 |
|---|---|
| Accounts receivable (1) | 123,912 |
| Inventory | 469,700 |
| Other current assets | 55,052 |
| Property, plant and equipment | 25,923 |
| Intangible assets | 4,750,000 |
| Goodwill | 459,164 |
| Other assets | 59,219 |
| Accounts payable and accrued liabilities | (205,466) |
| Deferred tax liabilities | (565,050) |
| Other long-term liabilities | (104,824) |
| Total assets and liabilities | $5,323,561 |
(1) The Company expects to collect all contractual accounts receivable based on information available as of the acquisition date.
The purchase price allocation presented above is preliminary as of June 30, 2026 and remains subject to revision during the measurement period, which extends up to one year from the acquisition date. The preliminary estimates of the fair values assigned to assets acquired and liabilities assumed, including identifiable intangible assets, deferred income taxes, and other acquired assets and assumed liabilities, are based on information available as of the filing date. As the Company obtains additional information and completes its valuation analyses, it may record adjustments to these preliminary amounts, with a corresponding adjustment to goodwill.
Intangible Assets
The fair values of the commercialized pharmaceutical products and in-process R&D (IPR&D) were determined using the multi-period excess earnings method. This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return. The discount rate used to determine the fair values of commercialized pharmaceutical products and IPR&D were 12.0% and 12.5%, respectively. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.
The following table presents details of the purchased intangible assets acquired:
| Estimated Useful Life (in Years) | Fair Value | |
|---|---|---|
| Commercialized pharmaceutical product – GALAFOLD | 11 | $3,000,000 |
| Commercialized pharmaceutical product – POMBILITI + OPFOLDA | 12 | 1,450,000 |
| IPR&D - BMN 820 | Indefinite | 300,000 |
| Total intangible assets | $4,750,000 |
The amortization expense related to acquired intangible assets for the three and six months ended June 30, 2026 was $69.0 million.
Inventory
The fair value of inventory acquired includes approximately $228.0 million step-up for GALAFOLD and POMBILITI + OPFOLDA. The fair value was primarily determined based on the estimated selling price of finished goods less the cost to complete the manufacturing process and selling effort. The amortization of the inventory step-up is recognized as a component of
Cost of Sales on the Company’s Consolidated Statements of Comprehensive Income as the inventory is sold. The amortization expense related to inventory step-up for the three and six months ended June 30, 2026 was $11.7 million.
Leases
The Company recorded lease liabilities of approximately $53.8 million, which represent the present value of remaining lease payments over the respective lease terms, with a corresponding right-of-use assets of approximately $46.1 million, which represent the estimated fair value based on current market rental rates. As of June 30, 2026, the right-of-use assets are presented in Other assets on the Company’s Condensed Consolidated Balance Sheets. As of June 30, 2026, the current portion of the lease liabilities is presented in Accounts payable and accrued liabilities whereas the non-current portion is presented in Other long-term liabilities on the Company’s Condensed Consolidated Balance Sheets.
Goodwill
The recognized goodwill is primarily attributed to a deferred tax liability associated with the acquired intangible assets and inventory step-up. Goodwill recognized for Amicus is not deductible for tax purposes.
Results of Operations and Pro forma Financial Information
The following table presents revenues and net earnings for Amicus since the acquisition date of April 27, 2026 through June 30, 2026:
| Amount | |
|---|---|
| Total revenue | $136,006 |
| Net loss | $(91,932) |
The unaudited pro forma results of operations for BioMarin as if the acquisition had occurred on January 1, 2025 are presented in the table below:
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Total revenue | $1,038,914 | $980,098 | $1,984,908 | $1,850,492 |
| Net income (loss) | $(208,458) | $97,347 | $(200,907) | $78,599 |
These unaudited pro forma results were based on estimates and assumptions, which the Company believes are reasonable. The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition and the cost of financing the acquisition had taken place at the beginning of fiscal 2025. The unaudited pro forma information includes adjustments such as inventory step-up, amortization for intangible assets acquired, stock-based compensation expense, interest expense for acquisition financing, transaction costs and related income tax effects.
The significant nonrecurring adjustments reflected in the unaudited pro forma information above include the impact of (i) transaction costs of $47.1 million, (ii) post-combination stock-based compensation expense of $13.0 million, and (iii) commitment fee of $22.8 million relating to bridge loan commitment, all of which have been recognized as if incurred on the assumed acquisition date of January 1, 2025.
(3)FINANCIAL INSTRUMENTS
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of the dates presented. There wereno marketable securities as of June 30, 2026, and all marketable securities as of December 31, 2025 were classified as available-for-sale.
| June 30, 2026 | |||||
|---|---|---|---|---|---|
| Amortized Cost | GrossUnrealizedGains | GrossUnrealizedLosses | Aggregate Fair Value | Cash and Cash Equivalents | |
| Level 1: | |||||
| Cash | $527,517 | $— | $— | $527,517 | $527,517 |
| Level 2: | |||||
| Money market instruments | 346,488 | — | — | 346,488 | 346,488 |
| Total | $874,005 | $— | $— | $874,005 | $874,005 |
| December 31, 2025 | |||||||
|---|---|---|---|---|---|---|---|
| Amortized Cost | GrossUnrealizedGains | GrossUnrealizedLosses | Aggregate Fair Value | Cash and Cash Equivalents | Short-termMarketableSecurities (1) | Long-termMarketableSecurities (2) | |
| Level 1: | |||||||
| Cash | $415,760 | $— | $— | $415,760 | $415,760 | $— | $— |
| Level 2: | |||||||
| Money market instruments | 895,919 | — | — | 895,919 | 895,919 | — | — |
| Corporate debt securities | 472,572 | 3,286 | (3) | 475,855 | — | 189,566 | 286,289 |
| U.S. government agency securities | 206,018 | 1,197 | (1) | 207,214 | — | 59,115 | 148,099 |
| Asset-backed securities | 57,687 | 420 | (4) | 58,103 | — | 249 | 57,854 |
| Subtotal | 1,632,196 | 4,903 | (8) | 1,637,091 | 895,919 | 248,930 | 492,242 |
| Total | $2,047,956 | $4,903 | $(8) | $2,052,851 | $1,311,679 | $248,930 | $492,242 |
(1) The Company’s short-term marketable securities as of December 31, 2025 matured inone year or less.
(2) The Company’s long-term marketable securities as of December 31, 2025 matured betweenone andfive years.
(4)SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION
Inventory consisted of the following:
| June 30,2026 | December 31,2025 | |
|---|---|---|
| Raw materials | $259,353 | $106,510 |
| Work-in-process | 1,240,090 | 801,061 |
| Finished goods | 283,081 | 391,312 |
| Total inventory | $1,782,524 | $1,298,883 |
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Property, Plant and Equipment, Net consisted of the following:
| June 30,2026 | December 31,2025 | |
|---|---|---|
| Property, plant and equipment, gross | $2,101,032 | $2,026,813 |
| Accumulated depreciation | (1,111,038) | (1,074,305) |
| Total property, plant and equipment, net | $989,994 | $952,508 |
Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended June 30, 2026 was $9.6 million and $18.4 million, respectively. Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended June 30, 2025 was $10.6 million and $24.8 million, respectively.
Intangible Assets, Net consisted of the following:
| June 30,2026 | December 31,2025 | |
|---|---|---|
| Finite-lived intangible assets | $5,173,642 | $723,966 |
| Indefinite-lived intangible assets | 300,000 | — |
| Gross intangible assets: | 5,473,642 | 723,966 |
| Accumulated amortization | (594,275) | (510,129) |
| Net carrying value | $4,879,367 | $213,837 |
Accounts Payable and Accrued Liabilities consisted of the following:
| June 30,2026 | December 31,2025 | |
|---|---|---|
| Accounts payable and accrued operating expenses | $406,977 | $312,768 |
| Accrued rebates payable | 243,526 | 166,925 |
| Accrued compensation expense | 220,506 | 219,422 |
| Accrued Interest | 47,129 | 907 |
| Foreign currency exchange forward contracts | 33,525 | 31,007 |
| Lease liability | 16,058 | 8,685 |
| Accrued royalties payable | 15,502 | 7,968 |
| Accrued income taxes | 9,137 | 3,667 |
| Other | 13,433 | 7,682 |
| Total accounts payable and accrued liabilities | $1,005,793 | $759,031 |
(5)FAIR VALUE MEASUREMENTS
The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 1 – Business Overview and Significant Accounting Policies to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Other than the Company’s debt obligations disclosed in Note 7 –Debt, there wereno financial assets or liabilities that were remeasured using quoted prices in active markets for identical assets (Level 1) as of June 30, 2026 or December 31, 2025. Other than assets acquired from the Amicus acquisition discussed in Note 2 -Acquisitions, the Company hadno financial assets or liabilities that are remeasured on a recurring or non-recurring basis using unobservable inputs that reflect estimates and assumptions (Level 3) as of June 30, 2026 or December 31, 2025.
Level 2 assets and liabilities that are remeasured using significant observable inputs consisted of the following, except for derivatives, which are discussed in Note 6 –Derivative Instruments and Hedging Strategiesand the Term Loan A Facility, which is discussed in Note 7 -Debt:
| June 30,2026 | December 31,2025 | |
|---|---|---|
| Assets: | ||
| Other current assets: | ||
| NQDC Plan assets | $4,541 | $3,765 |
| Other assets: | ||
| NQDC Plan assets | 45,417 | 41,689 |
| Total assets | $49,958 | $45,454 |
| Liabilities: | ||
| Accounts payable and accrued liabilities: | ||
| NQDC Plan liability | $4,541 | $3,765 |
| Other long-term liabilities: | ||
| NQDC Plan liability | 45,417 | 41,689 |
| Total liabilities | $49,958 | $45,454 |
There were no transfers between levels during the three and six months ended June 30, 2026.
(6)DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
The Company uses foreign currency exchange forward contracts (forward contracts) to protect against the impact of changes in the value of forecasted foreign currency cash flows resulting from revenues and operating expenses denominated in currencies other than the USD, primarily the Euro. Certain of these forward contracts are designated as cash flow hedges and have maturities of up totwo years. The Company also enters into forward contracts to manage foreign exchange risk related to asset or liability positions denominated in currencies other than USD. Such forward contracts are considered to be economic hedges, are not designated as hedging instruments and have maturities of up tothree months. The Company does not use derivative instruments for speculative trading purposes. The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.
The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented.
| Forward Contracts | June 30,2026 | December 31,2025 |
|---|---|---|
| Derivatives designated as hedging instruments: | ||
| Sell | $1,384,297 | $1,573,184 |
| Purchase | $306,940 | $385,499 |
| Derivatives not designated as hedging instruments: | ||
| Sell | $432,337 | $356,285 |
| Purchase | $96,696 | $36,798 |
The fair value of the Company’s derivatives, which are classified as Level 2 within the fair value hierarchy, were as follows:
| Balance Sheet Location | June 30,2026 | December 31,2025 |
|---|---|---|
| Derivatives designated as hedging instruments: | ||
| Derivative Assets | ||
| Other current assets | $30,413 | $17,585 |
| Other assets | 9,461 | 5,591 |
| Subtotal | $39,874 | $23,176 |
| Derivative Liabilities | ||
| Accounts payable and accrued liabilities | $33,066 | $30,134 |
| Other long-term liabilities | 7,554 | 9,905 |
| Subtotal | $40,620 | $40,039 |
| Derivatives not designated as hedging instruments: | ||
| Derivative Assets | ||
| Other current assets | $5,975 | $2,479 |
| Derivative Liabilities | ||
| Accounts payable and accrued liabilities | $459 | $873 |
| Total Derivative Assets | $45,849 | $25,655 |
| Total Derivative Liabilities | $41,079 | $40,912 |
For additional discussion of fair value measurements, see Note 5 - Fair Value Measurements.
The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.
| Three Months Ended June 30, · Six Months Ended June 30, | |||||
|---|---|---|---|---|---|
| 2026 · 2025 · 2026 · 2025 | |||||
| Derivatives Designated as Cash Flow Hedging Instruments · Cash Flow Hedging Gains (Losses) Reclassified into Earnings · Cash Flow Hedging Gains (Losses) Reclassified into Earnings | |||||
| Net product revenues | $(6,675) | $(2,063) | $(19,087) | $10,482 | |
| Operating expenses | $2,620 | $1,514 | $6,221 | $(1,092) | |
| Derivatives Not Designated as Hedging Instruments | Gains (Losses) Recognized in Earnings | Gains (Losses) Recognized in Earnings | |||
| Operating expenses | $(1,206) | $(24,070) | $(1,019) | $(36,179) | |
As of June 30, 2026, the Company expects to reclassify unrealized losses of $2.7 million from Accumulated Other Comprehensive Income (AOCI) to earnings as the forecasted revenues and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 8 –Accumulated Other Comprehensive Income.
(7)DEBT
As of June 30, 2026, the Company had outstanding fixed-rate notes and variable-rate term loans for an undiscounted aggregate principal amount of $4.3 billion. The debt detailed below incurs interest to be paid periodically in arrears. The following table summarizes information regarding the Company’s debt:
| June 30,2026 | December 31,2025 | |
|---|---|---|
| 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)(1) | $600,000 | $600,000 |
| 5.5% senior unsecured notes due in February 2034 (the 2034 Notes) | 850,000 | — |
| Term Loan A | 800,000 | — |
| Term Loan B | 2,000,000 | — |
| Total debt | 4,250,000 | 600,000 |
| Less: Unamortized discount and deferred offering costs | (63,858) | (2,824) |
| Total debt, net | $4,186,142 | $597,176 |
| Fair value of debt(2) : | June 30, 2026 |
|---|---|
| 2027 Notes | $584,762 |
| 2034 Notes | 835,176 |
| Term Loan A | 796,000 |
| Term Loan B | 2,002,500 |
| Total fair value of debt | $4,218,438 |
(1) For additional information related to the Company’s 2027 Notes, see Note 10 -Debt to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
(2) The fair value of the Company’s debts are based on open-market trades (Level 1 of the fair value hierarchy), except for the Term Loan A Facility, whose fair value was based on observable market inputs for comparable debt instruments (Level 2 of the fair value hierarchy). For additional discussion of fair value measurements, see Note 1 – Business Overview and Significant Accounting Policies to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Interest expense related to the Company’s debt and bridge loan commitment consisted of the following:
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Coupon interest expense | $41,167 | $1,875 | $49,972 | $3,750 |
| Bridge commitment fee | 17,492 | — | 22,813 | — |
| Accretion of discount on convertible notes and term loans | 1,571 | 485 | 2,058 | 970 |
| Amortization of debt issuance costs | 498 | 27 | 777 | 53 |
| Total interest expense on debt | $60,728 | $2,387 | $75,620 | $4,773 |
Term Loans and Revolving Credit Facility
In connection with the acquisition of Amicus in April 2026, the Company entered into a senior secured credit agreement (the 2026 Credit Agreement) consisting of an $800.0 million senior secured term loan A facility (Term Loan A Facility), a $2.0 billion senior secured term loan B facility (Term Loan B Facility, and, together with the Term Loan A Facility, the Term Facilities), and a $600.0 million senior secured revolving credit facility (the 2026 Revolving Facility). The proceeds from the Term Facilities were used to finance a portion of the acquisition consideration and related transaction costs. The Company incurred $46.2 million of issuance costs, which were deferred and will be amortized over the life of the Term Facilities and recorded as interest expense.
Borrowings under the Term Facilities and the 2026 Revolving Facility bear interest at variable rates based on Secured Overnight Financing Rate (SOFR) or an alternate base rate, plus an applicable margin as specified in the 2026 Credit Agreement. Interest on SOFR borrowings is payable at the end of each applicable interest period and, for interest periods greater than three months, at least quarterly.
The Term Loan A Facility matures on April 27, 2031 and requires quarterly principal repayments equal to 1.25% of the original principal amount, with the remaining outstanding principal balance due at maturity. The Term Loan B Facility matures on April 27, 2033 and requires quarterly principal repayments equal to 0.25% of the original principal amount, with the remaining outstanding principal balance due at maturity.
The 2026 Revolving Facility matures on April 27, 2031 and there wereno borrowings outstanding under the 2026 Revolving Facility as of June 30, 2026. The Company had the full $600.0 million of borrowing capacity available under the facility, subject to compliance with the terms of the 2026 Credit Agreement. The 2026 Credit Agreement contains customary affirmative and negative covenants, including, among others, covenants that restrict the Company's ability to incur additional indebtedness, create liens, make investments, pay dividends or make other restricted payments, dispose of assets, and enter into transactions with affiliates, in each case subject to exceptions set forth therein.
2034 Notes
In February 2026, the Company issued $850.0 million in aggregate principal amount of 5.5% senior unsecured notes with a maturity date of February 15, 2034, and the proceeds from the issuance were deposited into an escrow account and subsequently used to fund the Amicus acquisition. The 2034 Notes bear interest at the rate of 5.5% per annum. Interest is payable semi-annually with cash in arrears on February 15 and August 15 of each year, beginning August 15, 2026. Net proceeds from the offering were $832.3 million. The Company incurred $17.7 million of issuance costs, which were deferred and will be amortized over the life of the 2034 Notes and recorded as interest expense.
The indenture governing the Notes contains customary covenants that, among other things, restrict, with certain exceptions, the ability of the Company and its subsidiaries to incur additional debt, pay dividends, make certain other restricted payments, incur debt secured by liens, dispose of assets, engage in consolidations and mergers or sell or transfer all or substantially all of its assets. The offer and sale of the 2034 Notes have not been registered under the Securities Act or any state securities laws.
Bridge Commitment
In December 2025, the Company entered into a debt financing commitment letter and related fee letter with certain lenders, pursuant to which the lenders committed to provide the Company with debt financing up to approximately $3.7 billion (the Bridge Commitment) in the form of a 364-day senior secured bridge loan facility (Bridge Facility), the proceeds of which would be available for the acquisition of Amicus. In connection with the issuance of the 2034 Notes, the Bridge Commitment was reduced to $2.8 billion. Upon entry into the senior secured term loan facility in April 2026, the remaining Bridge Commitment was reduced tozero. As a result, the Company recognized approximately $17.5 million and $22.8 million of commitment fees during the three and six months ended June 30, 2026, respectively, which is presented as Interest expense on the Condensed Consolidated Statements of Comprehensive Income. Refer to Note 2 –Acquisitionsfor additional details related to the Amicus acquisition.
(8)ACCUMULATED OTHER COMPREHENSIVE INCOME
The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income and reclassifications out of AOCI, for the periods presented.
| Three Months Ended June 30, 2026 | |||
|---|---|---|---|
| Unrealized Gains(Losses) on CashFlow Hedges | Cumulative Translation Adjustment | Total | |
| AOCI balance as of March 31, 2026 | $(4,237) | $— | $(4,237) |
| Other comprehensive income (loss) before reclassifications | (564) | (8,037) | (8,601) |
| Less: gain (loss) reclassified from AOCI | (4,055) | — | (4,055) |
| Tax effect | — | — | — |
| Net current-period other comprehensive income (loss) | 3,491 | (8,037) | (4,546) |
| AOCI balance as of June 30, 2026 | $(746) | $(8,037) | $(8,783) |
| Three Months Ended June 30, 2025 | |||
|---|---|---|---|
| Unrealized Gains(Losses) on CashFlow Hedges | Unrealized Gains(Losses) onAvailable-for-SaleDebt Securities | Total | |
| AOCI balance as of March 31, 2025 | $16,233 | $2,918 | $19,151 |
| Other comprehensive income (loss) before reclassifications | (64,576) | 405 | (64,171) |
| Less: gain (loss) reclassified from AOCI | (549) | — | (549) |
| Tax effect | — | (94) | (94) |
| Net current-period other comprehensive income (loss) | (64,027) | 311 | (63,716) |
| AOCI balance as of June 30, 2025 | $(47,794) | $3,229 | $(44,565) |
| Six Months Ended June 30, 2026 | ||||
|---|---|---|---|---|
| Unrealized Gains(Losses) on CashFlow Hedges | Unrealized Gains(Losses) onAvailable-for-SaleDebt Securities | Cumulative Translation Adjustment | Total | |
| AOCI balance as of December 31, 2025 | $(17,244) | $3,771 | $— | $(13,473) |
| Other comprehensive income (loss) before reclassifications | 3,632 | (4,895) | (8,037) | (9,300) |
| Less: gain (loss) reclassified from AOCI | (12,866) | — | — | (12,866) |
| Tax effect | — | 1,124 | — | 1,124 |
| Net current-period other comprehensive income (loss) | 16,498 | (3,771) | (8,037) | 4,690 |
| AOCI balance as of June 30, 2026 | $(746) | $— | $(8,037) | $(8,783) |
| Six Months Ended June 30, 2025 | |||
|---|---|---|---|
| Unrealized Gains(Losses) on CashFlow Hedges | Unrealized Gains(Losses) onAvailable-for-SaleDebt Securities | Total | |
| AOCI balance as of December 31, 2024 | $59,824 | $1,829 | $61,653 |
| Other comprehensive income (loss) before reclassifications | (98,228) | 1,839 | (96,389) |
| Less: gain (loss) reclassified from AOCI | 9,390 | — | 9,390 |
| Tax effect | — | (439) | (439) |
| Net current-period other comprehensive income (loss) | (107,618) | 1,400 | (106,218) |
| AOCI balance as of June 30, 2025 | $(47,794) | $3,229 | $(44,565) |
For additional discussion of reclassifications from AOCI see Note 6 – Derivative Instruments and Hedging Strategies.
(9)SEGMENT INFORMATION
The Company operates and is managed asone business segment which derives revenue from activities related to the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions.
The Company’s commercial organization is responsible for marketing its approved products worldwide. The Company’s research and development (R&D) organization is responsible for research and discovery of new product candidates and supporting the development and registration efforts for potential new products. The Company’s technical operations group is responsible for the development of manufacturing processes, supplying clinical drug product, and the manufacturing and distribution of the Company’s commercial products. The Company is also supported by corporate staff functions.
The Company’s Chief Executive Officer, as the Chief Operating Decision Maker (CODM), manages and allocates resources to the operations of the total company by assessing the overall level of resources available and how to best allocate them to support the Company’s long-term company-wide strategic goals. In making this decision, the CODM uses consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods.
The key measure of segment profit or loss used by the CODM to allocate resources and assess the Company's performance is its Consolidated Net Income, as reported on the Condensed Consolidated Statements of Comprehensive Income. The CODM's analysis includes a comparison to budgeted results. Segment assets provided to the CODM are consistent with those reported on the Condensed Consolidated Balance Sheets with particular emphasis on the Company's available liquidity including cash, cash equivalents, investments, accounts receivable and inventory.
The following table includes information about segment revenue, significant segment expenses, and segment measure of profitability:
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Total revenues | $989,708 | $825,410 | $1,755,916 | $1,570,555 |
| Less: | ||||
| Cost of sales | 202,795 | 150,090 | 397,794 | 301,648 |
| R&D expenses | ||||
| Research and early pipeline | 85,069 | 95,968 | 172,360 | 186,438 |
| Later-stage clinical programs | 50,295 | 13,133 | 86,472 | 27,424 |
| Marketed products | 71,588 | 52,207 | 126,916 | 106,177 |
| SG&A expenses | ||||
| S&M expenses | 142,186 | 122,100 | 267,113 | 224,631 |
| G&A expenses | 253,363 | 110,179 | 386,726 | 213,764 |
| Other segment expense, net (1) | 139,650 | 41,201 | 168,246 | 84,255 |
| Net income | $44,762 | $240,532 | $150,289 | $426,218 |
(1)Other segment expense, net during the three and six months ended June 30, 2026 and 2025 include intangible asset amortization, interest income and expense, other income, net and income tax expense.
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| VOXZOGO | $252,528 | $221,391 | $472,408 | $435,145 |
| Metabolic Conditions (formerly Enzyme Therapies): | ||||
| VIMIZIM | 194,371 | 215,424 | 404,575 | 403,770 |
| NAGLAZYME | 135,255 | 128,867 | 265,329 | 243,157 |
| PALYNZIQ | 135,167 | 105,938 | 224,725 | 199,207 |
| GALAFOLD(1) | 105,748 | — | 105,748 | — |
| BRINEURA | 51,370 | 48,692 | 98,474 | 89,054 |
| ALDURAZYME | 43,539 | 56,437 | 80,281 | 105,414 |
| POMBILITI + OPFOLDA(1) | 30,258 | — | 30,258 | — |
| KUVAN | 24,444 | 27,034 | 48,324 | 52,170 |
| ROCTAVIAN | 11,713 | 9,199 | 14,349 | 19,709 |
| Total net product revenues | 984,393 | 812,982 | 1,744,471 | 1,547,626 |
| Royalty and other revenues | 5,315 | 12,428 | 11,445 | 22,929 |
| Total revenues | $989,708 | $825,410 | $1,755,916 | $1,570,555 |
(1) The Company commenced recognizing revenue related to GALAFOLD and POMBILITI + OPFOLDA on April 27, 2026 following its acquisition of Amicus. Refer to Note 2 -Acquisitions for additional information.
The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide.
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| United States | $371,074 | $272,554 | $614,018 | $514,248 |
| Europe | 297,498 | 243,138 | 516,334 | 472,716 |
| Latin America | 103,917 | 98,118 | 212,081 | 186,400 |
| Rest of world | 168,365 | 142,735 | 321,757 | 268,848 |
| Total net product revenues marketed by the Company | 940,854 | 756,545 | 1,664,190 | 1,442,212 |
| ALDURAZYME net product revenues marketed by Sanofi | 43,539 | 56,437 | 80,281 | 105,414 |
| Total net product revenues | $984,393 | $812,982 | $1,744,471 | $1,547,626 |
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Customer A | 13% | 15% | 14% | 15% |
| Customer B | 11 | 12 | 11 | 12 |
| Customer C | 11 | 11 | 10 | 11 |
| Total | 35% | 38% | 35% | 38% |
Concentration Information
On a consolidated basis, one customer accounted for 18% of the Company’s June 30, 2026 accounts receivable balance compared to two customers who accounted for 20% and 10%, respectively, of the accounts receivable balance as of December 31, 2025. As of June 30, 2026, and December 31, 2025, the accounts receivable balance for Sanofi included $157.6 million and $148.0 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.
The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, wars and military conflicts, impact of new or increased tariffs and escalating trade tensions, regulatory uncertainty, and supply chain disruptions, could affect the Company’s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate as of June 30, 2026 based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.
(10)STOCK-BASED COMPENSATION
The Company has stockholder-approved equity incentive plans that provide for the granting of RSUs and stock options as well as other forms of equity compensation to its employees, officers and non-employee directors. The Company also has an Employee Stock Purchase Plan (ESPP). Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows:
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Cost of sales | $5,005 | $4,156 | $8,596 | $6,347 |
| Research and development | 15,895 | 13,845 | 27,549 | 25,972 |
| Selling, general and administrative | 54,795 | 29,530 | 83,007 | 52,912 |
| Total stock-based compensation expense | $75,695 | $47,531 | $119,152 | $85,231 |
(11)RESTRUCTURING
Corporate Initiatives
In connection with the Company’s plan to simplify its organizational design and strategic initiatives, the Company committed to plans in the first quarter of 2026 to reduce its global workforce. Restructuring charges associated with the reorganization and strategic initiatives comprised of one-time cash expenditures for severance and other employee termination benefits. These reductions are expected to be substantially complete by the end of 2026.
Amicus Integration
In April 2026, the Company committed to a restructuring plan related to the integration of Amicus. This restructuring plan is intended to realize certain targeted synergies following the acquisition, primarily through reductions in overlapping personnel costs within the general and administrative functions. Restructuring charges associated with Amicus integration comprised of one-time cash expenditures for severance and other employee termination benefits. These reductions are expected to be completed in phases through April 2027.
Restructuring charges and adjustments were included in SG&A in the Condensed Consolidated Statements of Comprehensive Income. Restructuring charges consisted of the following:
| Three Months EndedJune 30, 2026 | Six Months EndedJune 30, 2026 | |
|---|---|---|
| Restructuring charges - Corporate initiatives | $3,282 | $11,594 |
| Restructuring charges - Amicus integration | 53,140 | 53,140 |
| $56,422 | $64,734 |
The following unpaid balance as of June 30, 2026 was recorded to Accounts Payable and Accrued Liabilities on the Condensed Consolidated Balance Sheets:
| Severance and related costs | |
|---|---|
| Balance as of December 31, 2025 | $3,180 |
| Additions and adjustments | 64,734 |
| Payments | (16,136) |
| Balance as of June 30, 2026 | $51,778 |
(12)EARNINGS PER COMMON SHARE
Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the ESPP, unvested RSUs and contingent issuances of common stock related to the Company’s convertible debt.
The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Numerator: | ||||
| Net income, basic | $44,762 | $240,532 | $150,289 | $426,218 |
| Add: Interest expense, net of tax, on the Company's convertible debt | — | 1,833 | — | 3,665 |
| Net income, diluted | $44,762 | $242,365 | $150,289 | $429,883 |
| Denominator: | ||||
| Weighted-average common shares outstanding, basic | 193,423 | 191,907 | 192,959 | 191,440 |
| Effect of dilutive securities: | ||||
| Common stock issuable under the Company's equity incentive plans | 1,044 | 819 | 1,188 | 838 |
| Common stock issuable under the Company’s convertible debt | — | 4,365 | — | 4,365 |
| Weighted-average common shares outstanding, diluted | 194,467 | 197,091 | 194,147 | 196,643 |
| Earnings per common share, basic | $0.23 | $1.25 | $0.78 | $2.23 |
| Earnings per common share, diluted | $0.23 | $1.23 | $0.77 | $2.19 |
In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands):
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Common stock issuable under the Company's equity incentive plans | 13,284 | 11,815 | 13,140 | 11,795 |
| Common stock issuable under the Company’s convertible debt | 4,365 | — | 4,365 | — |
| Total number of potentially issuable shares | 17,649 | 11,815 | 17,505 | 11,795 |
(13)COMMITMENTS AND CONTINGENCIES
Contingencies
From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable based on existing information. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. Liabilities are evaluated and refined each reporting period as additional information is known. Any receivables for insurance recoveries for these liability claims are recorded as assets when it is probable that a recovery will be realized.
As first disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, the Company received a subpoena from the U.S. Department of Justice (DOJ) requesting that the Company produce certain documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME. The Company has produced the requested documents in response to the subpoena and is cooperating fully. The Company is unable to make any assurances regarding the outcome of the investigation by the DOJ, or the impact, if any, that such investigation may have on the Company’s business and financial statements.
License Agreements
As part of the Amicus acquisition, the Company assumed the existing license agreement with Dimerix Limited (Dimerix) for the U.S. commercialization rights for DMX-200 (now known as BMN 820) for the treatment of FSGS and other indications. Pursuant to the agreement, if future development, regulatory or commercial milestones are met, the Company will be obligated to pay Dimerix up to a maximum aggregate amount of $510.0 million and tiered royalties of BMN 820 net sales in the U.S. ranging from the low-teens to low-twenties. Refer to Note 2 - Acquisitions for additional information on the acquisition.
Other Commitments
The Company uses experts and laboratories at universities and other institutions to perform certain R&D activities. These amounts are recorded as R&D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&D services, production services and facility construction services. As of June 30, 2026, such commitments were estimated at $854.4 million, of which $361.5 million is expected to be paid in 2026 as underlying goods and services are received. The Company has also licensed technology from third parties, for which it is required to pay royalties upon future sales, subject to certain annual minimums.
The following discussion of our financial condition and results of operations should be read in conjunction with our Condensed Consolidated Financial Statements and the related Notes thereto included in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In particular, we encourage you to review the risks and uncertainties described in “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q. These risks and uncertainties could cause actual results to differ significantly from those projected in forward-looking statements contained in this report or implied by past results and trends. Forward-looking statements are statements that attempt to forecast or anticipate future developments in our business, financial condition or results of operations. See the section titled “Forward-Looking Statements” that appears at the beginning of this Quarterly Report on Form 10-Q. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated), and, except as required by law, we undertake no obligation to update or revise these statements in light of future developments. Our Condensed Consolidated Financial Statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and are presented in U.S. Dollars (USD).
Overview
We are a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, our San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
On April 27, 2026, we completed the acquisition of Amicus Therapeutics, Inc. (Amicus). The results of operations of Amicus, along with the preliminary estimated fair values of assets acquired and liabilities assumed in the acquisition, have been included in the Condensed Consolidated Financial Statements since the closing of the acquisition on April 27, 2026. Refer to Note 2 –Acquisitions for additional details related to the Amicus acquisition.
A summary of our commercial products, as of June 30, 2026, is provided below:
| Commercial Products(1) | Indication |
|---|---|
| VOXZOGO (vosoritide) | Achondroplasia |
| Metabolic Conditions (formerly Enzyme Therapies): | |
| ALDURAZYME (laronidase) | MPS I |
| BRINEURA (cerliponase alfa) | Neuronal ceroid lipofuscinosis type 2 (CLN2) |
| GALAFOLD (migalastat HCl)(2) | Fabry |
| NAGLAZYME (galsulfase) | MPS VI |
| PALYNZIQ (pegvaliase-pqpz) | Phenylketonuria (PKU) |
| POMBILITI + OPFOLDA (cipaglucosidase alfa-atga/miglustat)(2) | Pompe |
| VIMIZIM (elosulfase alpha) | Mucopolysaccharidosis (MPS) IVA |
| KUVAN (sapropterin dihydrochloride) | PKU |
(1) In 2026, we announced that we will no longer market ROCTAVIAN. For additional information related to ROCTAVIAN, see Note 19 - Restructuring to the Consolidated Financial Statements accompanying our Annual Report on Form 10-K for the year ended December 31, 2025.
(2) We acquired two commercial products, GALAFOLD and POMBILITI + OPFOLDA, in connection with the acquisition of Amicus on April 27, 2026. Refer to Note 2 -Acquisitions to our accompanying Condensed Consolidated Financial Statements for additional information.
Financial Highlights
Key components of our results of operations include the following:
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Total revenues | $989.7 | $825.4 | $1,755.9 | $1,570.6 |
| Cost of sales | $202.8 | $150.1 | $397.8 | $301.6 |
| Research and development (R&D) | $207.0 | $161.3 | $385.7 | $320.0 |
| Selling, general and administrative (SG&A) | $395.5 | $232.3 | $653.8 | $438.4 |
| Intangible asset amortization | $73.5 | $4.8 | $78.0 | $9.7 |
| Interest expense | $63.3 | $2.7 | $78.3 | $5.5 |
| Provision for income taxes | $16.6 | $57.3 | $52.3 | $109.7 |
| Net income | $44.8 | $240.5 | $150.3 | $426.2 |
See “Results of Operations” below for discussion of our results for the periods presented.
Uncertainty Relating to Macroeconomic Environment
Conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, wars and military conflicts, impact of new or increased tariffs and escalating trade tensions, regulatory uncertainty, and supply chain disruptions, could impact our global revenue sources and our overall business operations. The extent and duration of such effects remain uncertain and difficult to predict. We are actively monitoring and managing our response and assessing actual and potential impacts to our operating results and financial condition, as well as developments in our business, which could further impact the developments, trends and expectations described below. See the risk factor, “Our business is affected by macroeconomic conditions.” described in “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q.
Recent Developments
We continued to grow our commercial business and advance our product candidate pipeline during 2026. We believe that the combination of our internal research programs, partnerships and acquisitions of external assets will allow us to continue to develop and commercialize innovative therapies for patients with serious and life-threatening rare diseases and medical conditions. We periodically conduct strategic portfolio assessment of research and development programs to determine which we believe have the strongest combination of scientific merit, opportunity for commercial success and potential value creation for stockholders. Based on such strategic portfolio assessments, certain programs that do not meet its threshold for further development and commercialization could be discontinued.
In July 2026, we submitted our supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of VOXZOGO for the treatment of hypochondroplasia following our announcement in May 2026 that the Phase 3 CANOPY-HCH-3 study met its primary endpoint.
In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.
In July 2026, BioMarin and the n-Lorem Foundation entered into a collaboration and global exclusive license agreement to develop a potential first-in-disease antisense oligonucleotide (ASO) medicine for ReNU syndrome, a serious, rare neurodevelopmental condition with no approved targeted therapies.
In June 2026, the European Commission approved PALYNZIQ for adolescents 12 years and older with PKU. In February 2026, FDA approved PALYNZIQ for adolescents 12 years of age and older with PKU.
In May 2026, we announced that BMN 401 did not meet one of its two co-primary endpoints for the treatment of ENPP1 deficiency. Following the pivotal ENERGY 3 trial data readout, in August 2026, we made the decision to discontinue development of BMN 401 across all indications.
In April 2026, we acquired Amicus which is expected to strengthen our commercial portfolio with the addition of GALAFOLD and POMBILITI + OPFOLDA. We also acquired U.S. rights to BMN 820 (formerly DMX-200), a potential first-in-class oral CCR2 inhibitor for focal segmental glomerulosclerosis (FSGS). See Note 2 - Acquisitions to our accompanying Condensed Consolidated Financial Statements for additional information regarding the acquisition.
In April 2026, we obtained senior secured term loan facilities for $2.8 billion in aggregate principal. In February 2026, we issued $850.0 million in aggregate principal amount of 5.5% senior unsecured notes due 2034 (the 2034 Notes). The proceeds from the secured term loan facilities and the 2034 Notes were used to finance a portion of the Amicus acquisition. See “Financial Condition, Liquidity and Capital Resources” below for additional information regarding our indebtedness.
In April 2026, the first patient was enrolled in the registration-enabling Phase 2/3 study of BMN 333, our long-acting C-type natriuretic peptide (CNP) for achondroplasia.
See the risk factors described under “Business and Operational Risks” section in “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.